泽璟制药注射用ZG006获得FDA孤儿药资格认定

Core Viewpoint - ZaiJing Pharmaceutical (688266) has received orphan drug designation from the FDA for its investigational product ZG006, intended for the treatment of neuroendocrine cancer, which will facilitate its subsequent research, registration, and commercialization in the U.S. [1] Group 1 - The orphan drug designation provides ZaiJing Pharmaceutical with various policy supports, including tax credits for clinical trial costs [1] - The company will be exempt from new drug application fees as a result of this designation [1] - ZG006 will enjoy seven years of market exclusivity, independent of patent considerations [1]